## Brian Mayer | 22-ERD-007

### Executive Summary

We will address a critical lack of efficacious medical countermeasures to treat exposure to emergent, highly toxic, A-series, organophosphorus nerve agents. We will develop a fundamental understanding of A-series/cholinesterase biochemistry, as well as practical candidate countermeasures, through a large-scale drug discovery campaign.